WuXi XDC eyes IPO to boost ADC, bioconjugate manufacturing footprint

WuXi XDC is go­ing to list on the Hong Kong Ex­change on Nov. 17, with plans to raise ap­prox­i­mate­ly HK$3.4 bil­lion ($437.7 mil­lion) to ex­pand its man­u­fac­tur­ing ca­pa­bil­i­ties.

WuXi XDC is a con­tract re­search, de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CRD­MO) that spe­cial­izes in an­ti­body-drug con­ju­gates and bio­con­ju­gates. Fol­low­ing the IPO, WuXi Bi­o­log­ics will own 50.91% of the CRD­MO and WuXi STA will own 33.94%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.